- Home
- NVCT vs EARN Comparison
NVCT vs EARN Comparison
Compare NVCT & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCT
- EARN
- Stock Information
- Founded
- NVCT 2020
- EARN 2012
- Country
- NVCT United States
- EARN United States
- Employees
- NVCT N/A
- EARN N/A
- Industry
- NVCT Medicinal Chemicals and Botanical Products
- EARN Real Estate Investment Trusts
- Sector
- NVCT Health Care
- EARN Real Estate
- Exchange
- NVCT Nasdaq
- EARN Nasdaq
- Market Cap
- NVCT 170.3M
- EARN 187.6M
- IPO Year
- NVCT 2022
- EARN 2013
- Fundamental
- Price
- NVCT $8.87
- EARN $5.34
- Analyst Decision
- NVCT Strong Buy
- EARN Hold
- Analyst Count
- NVCT 3
- EARN 3
- Target Price
- NVCT $15.67
- EARN $5.88
- AVG Volume (30 Days)
- NVCT 128.2K
- EARN 1.2M
- Earning Date
- NVCT 05-06-2025
- EARN 05-13-2025
- Dividend Yield
- NVCT N/A
- EARN 17.96%
- EPS Growth
- NVCT N/A
- EARN N/A
- EPS
- NVCT N/A
- EARN 0.28
- Revenue
- NVCT N/A
- EARN $41,240,000.00
- Revenue This Year
- NVCT N/A
- EARN N/A
- Revenue Next Year
- NVCT N/A
- EARN $16.65
- P/E Ratio
- NVCT N/A
- EARN $19.12
- Revenue Growth
- NVCT N/A
- EARN N/A
- 52 Week Low
- NVCT $4.44
- EARN $4.33
- 52 Week High
- NVCT $11.80
- EARN $7.26
- Technical
- Relative Strength Index (RSI)
- NVCT 51.36
- EARN 48.90
- Support Level
- NVCT $8.70
- EARN $4.33
- Resistance Level
- NVCT $10.19
- EARN $5.20
- Average True Range (ATR)
- NVCT 0.93
- EARN 0.26
- MACD
- NVCT -0.08
- EARN 0.06
- Stochastic Oscillator
- NVCT 40.45
- EARN 72.14
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.